A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants 60 Years of Age and Older (ARIES)

ClinicalTrials.gov ID: NCT07717840

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07717840. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase I/II, Randomized, Double-Blind, Active-Controlled Study to Characterize the Safety and Immunogenicity of AZD6489 in Adults 60 Years of Age and Older

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This Phase I/II study is to characterize the safety and immunogenicity of 2 dose levels of AZD6489, an investigational RSV recombinant prefusion F protein VLP vaccine.

Study identification

NCT ID: NCT07717840
Recruitment status: Active, not recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: AstraZeneca; Industry
Enrollment: 164 participants

Conditions and interventions

Conditions

RSV Respiratory Syncytial Virus

Interventions

Biological

Eligibility (public fields only)

Age range: 60 Years and older
Sex: All
Healthy volunteers: Accepts healthy volunteers

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 8, 2026 (Actual)
Primary completion: Oct 1, 2026 (Actual)
Completion: Aug 19, 2027 (Estimated)
Last update posted: Oct 29, 2026

2026 – 2027

United States locations

U.S. sites: 6
U.S. states: 5
U.S. cities: 6

Facility	City	State	ZIP	Site status
Research Site	Long Beach	California	90815	—
Research Site	Rolling Hills Estates	California	90274	—
Research Site	Chicago	Illinois	60640	—
Research Site	Lenexa	Kansas	66219	—
Research Site	Kansas City	Missouri	64114	—
Research Site	Omaha	Nebraska	68134	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07717840, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Oct 29, 2026 · Synced Nov 14, 2026